Oppenheimer & Co’s Aerie Pharmaceuticals AERI Stock Holding History

Oppenheimer & Co’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$178K	–	1580
2021 Q1	$178K	Buy	+10,000	New	+$173K	﹤0.01%	1363
2020 Q4	–	Sell	-10,150	Closed	-$119K	–	1426
2020 Q3	$119K	Buy	10,150 +100	+1%	+$1.22K	﹤0.01%	1221
2020 Q2	$148K	Sell	10,050 -2,450	-20%	-$36.2K	﹤0.01%	1163
2020 Q1	$168K	Sell	12,500 -3,300	-21%	-$62.6K	0.01%	1056
2019 Q4	$382K	Sell	15,800 -6,095	-28%	-$126K	0.01%	939
2019 Q3	$421K	Sell	21,895 -7,359	-25%	-$169K	0.01%	858
2019 Q2	$864K	Buy	29,254 +22,461	+331%	+$865K	0.02%	639
2019 Q1	$323K	Buy	+6,793	New	+$299K	0.01%	1009

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Oppenheimer & Co's AERI Position: Q2 2021 in Review

Oppenheimer & Co sold out of Aerie Pharmaceuticals (AERI) in Q2 2021, closing a stake of 10,000 shares — an estimated $178K sold.

Oppenheimer & Co first reported a position in AERI in Q1 2019 and held it in 8 quarters. The position peaked at $864K in Q2 2019. 142 funds tracked by Wall St. Rank hold AERI as of Q2 2021.

Oppenheimer & Co reported no remaining Aerie Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Oppenheimer & Co sold 10,000 Aerie Pharmaceuticals shares in Q2 2021, an estimated $178K.
Oppenheimer & Co first reported a position in Aerie Pharmaceuticals in Q1 2019 and held it in 8 quarters.
Oppenheimer & Co's Aerie Pharmaceuticals position peaked at $864K in Q2 2019.
142 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2021.

Based on Oppenheimer & Co's 13F filing for Q2 2021, filed 3 Aug 2021.